Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142


Clinical Phenotype of Diabetic Peripheral Neuropathy and Relation to Symptom Patterns: Cluster and Factor Analysis in Patients with Type 2 Diabetes in Korea.

Won JC, Im YJ, Lee JH, Kim CH, Kwon HS, Cha BY, Park TS.

J Diabetes Res. 2017;2017:5751687. doi: 10.1155/2017/5751687. Epub 2017 Dec 13.


Factors affecting the cultural competence of visiting nurses for rural multicultural family support in South Korea.

Suk MH, Oh WO, Im Y.

BMC Nurs. 2018 Jan 8;17:1. doi: 10.1186/s12912-017-0269-4. eCollection 2018.


Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs.

Lee MA, Tan L, Yang H, Im YG, Im YJ.

Sci Rep. 2017 Dec 4;7(1):16837. doi: 10.1038/s41598-017-17082-x.


Prevalence and detection of low-allele-fraction variants in clinical cancer samples.

Shin HT, Choi YL, Yun JW, Kim NKD, Kim SY, Jeon HJ, Nam JY, Lee C, Ryu D, Kim SC, Park K, Lee E, Bae JS, Son DS, Joung JG, Lee J, Kim ST, Ahn MJ, Lee SH, Ahn JS, Lee WY, Oh BY, Park YH, Lee JE, Lee KH, Kim HC, Kim KM, Im YH, Park K, Park PJ, Park WY.

Nat Commun. 2017 Nov 9;8(1):1377. doi: 10.1038/s41467-017-01470-y.


NanoString nCounter® Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry.

Hyeon J, Cho SY, Hong ME, Kang SY, Do I, Im YH, Cho EY.

J Breast Cancer. 2017 Sep;20(3):286-296. doi: 10.4048/jbc.2017.20.3.286. Epub 2017 Sep 22.


PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients.

Iwata H, Im SA, Masuda N, Im YH, Inoue K, Rai Y, Nakamura R, Kim JH, Hoffman JT, Zhang K, Giorgetti C, Iyer S, Schnell PT, Bartlett CH, Ro J.

J Glob Oncol. 2017 Apr 11;3(4):289-303. doi: 10.1200/JGO.2016.008318. eCollection 2017 Aug.


Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.

Kim JY, Lee E, Park K, Park WY, Jung HH, Ahn JS, Im YH, Park YH.

Oncotarget. 2017 Jul 18;8(29):47400-47411. doi: 10.18632/oncotarget.17653.


Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.

Kim JY, Lee E, Park K, Park WY, Jung HH, Ahn JS, Im YH, Park YH.

Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881.


The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.

Ahn R, Sabourin V, Bolt AM, Hébert S, Totten S, De Jay N, Festa MC, Young YK, Im YK, Pawson T, Koromilas AE, Muller WJ, Mann KK, Kleinman CL, Ursini-Siegel J.

Nat Commun. 2017 Mar 9;8:14638. doi: 10.1038/ncomms14638.


Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.

Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L.

Breast Cancer Res. 2017 Feb 9;19(1):16. doi: 10.1186/s13058-017-0806-9.


The effect of androgen receptor expression on clinical characterization of metastatic breast cancer.

Kim JY, Park K, Lee E, Jung HH, Ahn JS, Im YH, Park WY, Park YH.

Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414.


Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P.

J Clin Oncol. 2017 Jan 10;35(2):141-148. Epub 2016 Nov 7.


Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period.

Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY.

J Pathol Transl Med. 2017 Jan;51(1):69-78. doi: 10.4132/jptm.2016.10.05. Epub 2016 Dec 25.


Clinical Implications of Obstructed Hemivagina and Ipsilateral Renal Anomaly (OHVIRA) Syndrome in the Prepubertal Age Group.

Han JH, Lee YS, Im YJ, Kim SW, Lee MJ, Han SW.

PLoS One. 2016 Nov 18;11(11):e0166776. doi: 10.1371/journal.pone.0166776. eCollection 2016.


Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer.

Hyun SH, Ahn HK, Lee JH, Choi JY, Kim BT, Park YH, Im YH, Lee JE, Nam SJ, Lee KH.

PLoS One. 2016 Oct 31;11(10):e0165814. doi: 10.1371/journal.pone.0165814. eCollection 2016.


Treatment of acute carbon monoxide poisoning with induced hypothermia.

Oh BJ, Im YG, Park E, Min YG, Choi SC.

Clin Exp Emerg Med. 2016 Jun 30;3(2):100-104. eCollection 2016 Jun.


Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.

Kim SH, Jung KH, Kim TY, Im SA, Choi IS, Chae YS, Baek SK, Kang SY, Park S, Park IH, Lee KS, Choi YJ, Lee S, Sohn JH, Park YH, Im YH, Ahn JH, Kim SB, Kim JH.

Cancer Res Treat. 2016 Oct;48(4):1373-1381. Epub 2016 Mar 23.


Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea.

Kim HK, Ham JS, Byeon S, Yoo KH, Jung KS, Song HN, Cho J, Lee JY, Lim SH, Kim HS, Kim JY, Lee JE, Kim SW, Nam SJ, Lee SK, Bae SY, Ahn JS, Im YH, Park YH.

Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11.


Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer.

Kim JY, Park K, Jung HH, Lee E, Cho EY, Lee KH, Bae SY, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH, Park YH.

Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18.

Supplemental Content

Loading ...
Support Center